Skip to main
NERV

Minerva Neurosciences (NERV) Stock Forecast & Price Target

Minerva Neurosciences (NERV) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Minerva Neurosciences is well-positioned for long-term success with a promising drug in its pipeline, a well-structured development plan, and strong leadership. The potential for blockbuster sales in a large global market makes this stock an attractive investment opportunity. However, regulatory risks should be closely monitored as the drug targets unique receptors. With a solid financial foundation and experienced leadership, Minerva Neurosciences shows potential for significant growth and profitability in the future.

Bears say

Minerva Neurosciences is currently focused on the development and commercialization of proprietary product candidates to treat CNS diseases, with a primary focus on its leading product Roluperidone. However, challenges lie ahead as Minerva must execute a successful confirmatory Phase 3 trial for the treatment of negative symptoms in patients with schizophrenia. Despite promising results in previous trials, a high placebo response rate remains a key concern, and the company must continue to carefully manage this in order to achieve regulatory approval. Additionally, concerns remain around the company's financials, with negligible product sales and reliance on external funding sources, such as the recent private placement and shelf offering, to continue operations.

Minerva Neurosciences (NERV) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Minerva Neurosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Minerva Neurosciences (NERV) Forecast

Analysts have given Minerva Neurosciences (NERV) a Buy based on their latest research and market trends.

According to 3 analysts, Minerva Neurosciences (NERV) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Minerva Neurosciences (NERV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.